A decision is expected in the fourth quarter of 2025.

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

If you're starting a semaglutide GLP-1 RA medication like Wegovy or Ozempic for weight loss, you may be wondering how soon ...

Weight loss continued to progress over the next ... the Wegovy study we mentioned above found that those taking a 2.4 mg dose of semaglutide lost about. Beyond the one-year mark, semaglutide ...

Diabetes is a long-term condition where too much sugar stays in the blood. If not managed well, it can get worse over time, ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Nearly two in three people with fatty liver disease lost some of the liver fat and inflammation after using semaglutide 2.4 ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...